发明授权
EP1244455B1 METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY
有权
方法血管疾病的处理中产生的BY功能不全硝酸标签
- 专利标题: METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY
- 专利标题(中): 方法血管疾病的处理中产生的BY功能不全硝酸标签
-
申请号: EP00976651.0申请日: 2000-10-27
-
公开(公告)号: EP1244455B1公开(公告)日: 2009-07-22
- 发明人: LOSCALZO, Joseph , VITA, Joseph, A. , LOBERG, Michael, D. , WORCEL, Manuel
- 申请人: Nitromed, Inc. , Trustees of Boston University
- 申请人地址: 12 Oak Park Drive Bedford, MA 01730 US
- 专利权人: Nitromed, Inc.,Trustees of Boston University
- 当前专利权人: Nitromed, Inc.,Trustees of Boston University
- 当前专利权人地址: 12 Oak Park Drive Bedford, MA 01730 US
- 代理机构: Wright, Robert Gordon McRae
- 优先权: US162230P 19991029; US179020P 20000131
- 国际公布: WO2001035961 20010525
- 主分类号: A61K31/535
- IPC分类号: A61K31/535 ; A61K31/50 ; A61K31/495 ; A61K31/415 ; A61K31/355 ; A61K31/34 ; A61K31/19 ; A61K31/135 ; A01N45/00
摘要:
The present invention provides methods of treating and/or preventing vascular diseases where nitric oxide insufficiency is a contributing factor by administering a therapeutically effective amount of at least one antioxidant, or a pharmaceutically acceptable salt thereof, and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenegic blocker, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angioetnsin II receptor antagonist, nitrosated renin inhibitor, and/or at least one compound used to treat cardiovascular diseases. The antioxidant is preferably a hydralazine compound or a pharmaceutically acceptable salt thereof. The present invention also provides methods of treating and/or preventing vascular diseases where nitric oxide insufficiency is a contributing factor by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and, optionally, at least one antioxidant and/or at least one compound used to treat cardiovascular diseases. The present invention also provides methods of treating and/or preventing Raynaud's syndrome by administering a therapeutically effective amount of at least one antioxidant and at least one of isosorbide dinitrate and isosorbide mononitrate and/or at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated alcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist nitrosated renin inhibitor. The present invention also provides novel transdermal patches comprising at least one antioxydant and at least one of isosorbide dinitrate and isosorbide mononitrate and/or at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor.
公开/授权文献
信息查询